Biotech stocks weathered a tumultuous 2Q12—including Europe's debt crisis and the aftermath of the bungled initial public offering (IPO) by social media bellwether Facebook—ending the quarter up 5% compared with the general indices. Fundraising was down in all categories compared with a year ago, with $7 billion raised in total (excluding partnership monies). Money raised from IPOs was down 29% to $133.2 million, with only two companies—Supernus and Tesaro—going public. Venture capital pumped in $1.2 billion last quarter, down from $1.5 billion a year ago.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Yang, W. Biotech weathers 2Q12 slump. Nat Biotechnol 30, 738 (2012). https://doi.org/10.1038/nbt.2332
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.2332
